- Home
- USAC vs MLYS Comparison
USAC vs MLYS Comparison
Compare USAC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USAC
- MLYS
- Stock Information
- Founded
- USAC 1998
- MLYS 2019
- Country
- USAC United States
- MLYS United States
- Employees
- USAC N/A
- MLYS N/A
- Industry
- USAC Natural Gas Distribution
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- USAC Utilities
- MLYS Health Care
- Exchange
- USAC Nasdaq
- MLYS Nasdaq
- Market Cap
- USAC 2.9B
- MLYS 3.1B
- IPO Year
- USAC N/A
- MLYS 2023
- Fundamental
- Price
- USAC $23.55
- MLYS $37.06
- Analyst Decision
- USAC Hold
- MLYS Strong Buy
- Analyst Count
- USAC 4
- MLYS 6
- Target Price
- USAC $25.50
- MLYS $42.60
- AVG Volume (30 Days)
- USAC 297.6K
- MLYS 1.5M
- Earning Date
- USAC 11-04-2025
- MLYS 11-10-2025
- Dividend Yield
- USAC 8.82%
- MLYS N/A
- EPS Growth
- USAC 24.37
- MLYS N/A
- EPS
- USAC 0.66
- MLYS N/A
- Revenue
- USAC $981,219,000.00
- MLYS N/A
- Revenue This Year
- USAC $7.21
- MLYS N/A
- Revenue Next Year
- USAC $4.61
- MLYS N/A
- P/E Ratio
- USAC $35.88
- MLYS N/A
- Revenue Growth
- USAC 8.22
- MLYS N/A
- 52 Week Low
- USAC $21.24
- MLYS $8.24
- 52 Week High
- USAC $30.10
- MLYS $41.09
- Technical
- Relative Strength Index (RSI)
- USAC 45.85
- MLYS 62.03
- Support Level
- USAC $23.81
- MLYS $37.48
- Resistance Level
- USAC $24.30
- MLYS $40.91
- Average True Range (ATR)
- USAC 0.51
- MLYS 2.15
- MACD
- USAC -0.03
- MLYS -0.90
- Stochastic Oscillator
- USAC 38.20
- MLYS 25.89
About USAC USA Compression Partners LP Common Units Representing Limited Partner Interests
USA Compression Partners LP provides compression services in the United States in terms of total compression fleet horsepower to customers relating to infrastructure applications, including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment. The company provides compression services in several shale plays throughout the U.S., including the Utica, Marcellus, Permian, Denver-Julesburg, Eagle Ford, Mississippi Lime, Granite Wash, Woodford, Barnett, and Haynesville.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.